PUBLISHER: Markets & Data | PRODUCT CODE: 1722098
PUBLISHER: Markets & Data | PRODUCT CODE: 1722098
Phage Therapy Market Assessment, By Targeted Bacteria, By Indication, By Route of Administration, By Distribution Channel, By Region, Opportunities and Forecast, 2018-2032F
Global phage therapy market is projected to witness a CAGR of 3.73% during the forecast period 2025-2032, growing from USD 1508 million in 2024 to USD 2021.85 million in 2032. The rising global threat of antibiotic-resistant infections, coupled with increasing clinical research and regulatory support, is driving the growth of the phage therapy market. Technological advancements in precision medicine and genetic engineering are enhancing phage efficacy and treatment customization. Additionally, growing healthcare investments across North America and Europe are accelerating product development and market adoption.
In June 2023, Adaptive Phage Therapeutics secured an investment of USD 12 million from funds overseen by Deerfield Management and the AMR Action Fund to further develop their pioneering phage therapy platform.
Rising Global Concern Over Antibiotic Resistance
The escalating challenge of antibiotic resistance is a major factor propelling the global phage therapy market. Conventional antibiotics are increasingly ineffective against resistant bacterial strains, resulting in extended illnesses, increased healthcare expenses, and higher mortality rates. Phage therapy presents a precise and innovative method by utilizing bacteriophages to specifically target and eliminate pathogenic bacteria while preserving beneficial microorganisms. This targeted approach minimizes the collateral damage typically associated with antibiotics and improves patient outcomes. Health authorities around the world are advocating research investments in alternative antimicrobial strategies. Furthermore, partnerships between biotechnology companies and healthcare organizations are expediting clinical trials for phage therapies. This intensified emphasis on alternatives is fostering a conducive environment for market growth. For example, in February 2025, the World Health Organization (WHO) highlighted the urgent need for alternatives such as phage therapy in its Global Antimicrobial Resistance and Use Surveillance System (GLASS) report.
Rapid Advancements in GLP-1 and Multi-Target Therapeutics
The advancement of segment-specific innovation is propelling the growth of the phage therapy market, particularly through the introduction of glucagon-like peptide-1 (GLP-1) receptor agonists. These therapies facilitate weight loss by increasing feelings of fullness and decreasing appetite, while also providing metabolic advantages such as improved glycemic control. Pharmaceutical companies are currently investigating multi-target medications that integrate GLP-1, amylin, or GIP mechanisms to enhance therapeutic outcomes. As new drug candidates exhibit greater efficacy in clinical trials compared to previous therapies, the interest in this mechanism of action is steadily increasing. This trend is leading to a surge in investments in clinical research and development, expansion of drug pipelines, and expedited regulatory processes for innovative medications. For example, in December 2023, Armata Pharmaceuticals reported favorable Phase Ib/IIa clinical trial outcomes for its phage therapy candidate AP-PA02 aimed at treating Pseudomonas aeruginosa infections.
Rising Investments and Positive Clinical Trial Results Accelerating Phage Therapy Development
The global market for phage therapy is experiencing significant growth, driven by increased investments and successful clinical results, especially in combating drug-resistant bacterial infections. Favorable outcomes from clinical trials of engineered phage therapies are motivating regulatory agencies and funding organizations to enhance their support for research and development initiatives. The emphasis on precision-targeted treatments is becoming essential as the prevalence of multidrug-resistant infections escalates globally. This development not only enhances the reputation of phage therapies among healthcare professionals but also expedites their journey towards commercialization. Additionally, financial backing from government entities highlights the promise of phage-based therapies as a legitimate alternative to traditional antibiotics, opening new opportunities for biotechnology companies. For instance, Locus Biosciences, Inc. ("Locus"), a clinical-stage biotechnology company that is at the forefront of developing a new class of precision-engineered bacteriophage therapies for various bacterial infections, announced positive results from Part 1 of its two-part Phase 2 ELIMINATE trial. This Phase 2 investigation is evaluating LBP-EC01, a CRISPR-Cas3 genetically modified bacteriophage therapy designed to treat uncomplicated urinary tract infections (uUTIs) caused by antimicrobial-resistant (AMR) and multi-drug-resistant (MDR) Escherichia coli (E. coli).
North America Maintains Market Leadership
North America leads the global phage therapy market, primarily due to substantial research funding, a well-established healthcare system, and active institutional backing. This region is home to numerous prominent phage therapy developers, academic research institutions, and government initiatives that promote antimicrobial innovation. Agencies such as the NIH, BARDA, and CARB-X are making significant investments in phage research programs to address the challenges posed by antibiotic resistance. Furthermore, there is an increasing trend among hospitals in the United States and Canada to engage in collaborative clinical trials assessing phage therapies for compassionate use. The combination of a strong regulatory environment and the rising incidence of multidrug-resistant infections ensures that North America will continue to hold its dominant position. In September 2023, the National Institutes of Health (NIH) awarded USD 5.7 million to the J. Craig Venter Institute (JCVI) to support a project focused on developing a phage therapeutic cocktail for treating antibiotic-resistant Klebsiella pneumoniae infections.
Future Market Scenario (2025-2032F)
The global market for phage therapy is set to experience significant expansion in the coming decade, fueled by the pressing demand for alternatives to traditional antibiotics in light of escalating antimicrobial resistance. As advancements in precision medicine continue, phage therapy's ability to selectively target bacteria while preserving healthy microbiota positions it as a highly promising solution. An increase in clinical trials, regulatory backing, and investments in biotechnological innovation are anticipated to broaden its therapeutic applications in areas such as infectious diseases, chronic wounds, and cystic fibrosis. Furthermore, technological advancements, including engineered phages and customized phage cocktails, are expected to improve treatment effectiveness. With North America and Europe at the forefront of research and regulatory approvals, emerging markets in the Asia-Pacific region are also making significant investments, paving the way for wider commercialization opportunities by the early 2030s.
Key Players Landscape and Outlook
The key players in the market are significantly investing in the development of phage therapy and are utilizing strategies such as mergers, acquisitions, partnerships, and new product launches to improve their services and competitiveness. Such efforts will propel significant growth in the market, allowing large-cap industry players to increase their presence and, therefore, find new opportunities in this market.
For example, in May 2023, Adaptive Phage Therapeutics established a licensing agreement with the Phage Therapy Center (IPTC) at the Hebrew University of Jerusalem and Hadassah Medical Center, aimed at identifying multiple phages that exhibit remarkably extensive efficacy against antibiotic-resistant bacteria.
Table of Contents
1. Project Scope and Definitions
2. Research Methodology
3. Executive Summary
4. Global Phage Therapy Market Outlook, 2018-2032F
- 4.1. Market Size Analysis & Forecast
- 4.1.1. By Value
- 4.2. Market Share Analysis & Forecast
- 4.2.1. By Targeted Bacteria
- 4.2.1.1. Escherichia coli
- 4.2.1.2. Staphylococcus aureus
- 4.2.1.3. Streptococcus
- 4.2.1.4. Pseudomonas aeruginosa
- 4.2.1.5. Salmonella
- 4.2.1.6. Other Bacteria
- 4.2.2. By Indication
- 4.2.2.1. Urinary Tract Infections
- 4.2.2.2. Chronic Otitis
- 4.2.2.3. Dental Extraction
- 4.2.2.4. Chronic Ulcerative Colitis
- 4.2.2.5. Bone Infection
- 4.2.2.6. Wound and Skin Infections
- 4.2.2.7. Cystic Fibrosis
- 4.2.2.8. Others
- 4.2.3. By Route of Administration
- 4.2.3.1. Oral
- 4.2.3.2. Topical
- 4.2.3.3. Parenteral
- 4.2.4. By Distribution Channel
- 4.2.4.1. Hospital Pharmacies
- 4.2.4.2. Retail Pharmacies
- 4.2.4.3. Online Pharmacies
- 4.2.5. By Region
- 4.2.5.1. North America
- 4.2.5.2. Europe
- 4.2.5.3. Asia-Pacific
- 4.2.5.4. South America
- 4.2.5.5. Middle East and Africa
- 4.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
- 4.2.1. By Targeted Bacteria
- 4.3. Market Map Analysis, 2024
- 4.3.1. By Targeted Bacteria
- 4.3.2. By Indication
- 4.3.3. By Route of Administration
- 4.3.4. By Distribution Channel
- 4.3.5. By Region
5. North America Phage Therapy Market Outlook, 2018-2032F
- 5.1. Market Size Analysis & Forecast
- 5.1.1. By Value
- 5.2. Market Share Analysis & Forecast
- 5.2.1. By Targeted Bacteria
- 5.2.1.1. Escherichia coli
- 5.2.1.2. Staphylococcus aureus
- 5.2.1.3. Streptococcus
- 5.2.1.4. Pseudomonas aeruginosa
- 5.2.1.5. Salmonella
- 5.2.1.6. Other Bacteria
- 5.2.2. By Indication
- 5.2.2.1. Urinary Tract Infections
- 5.2.2.2. Chronic Otitis
- 5.2.2.3. Dental Extraction
- 5.2.2.4. Chronic Ulcerative Colitis
- 5.2.2.5. Bone Infection
- 5.2.2.6. Wound and Skin Infections
- 5.2.2.7. Cystic Fibrosis
- 5.2.2.8. Others
- 5.2.3. By Route of Administration
- 5.2.3.1. Oral
- 5.2.3.2. Topical
- 5.2.3.3. Parenteral
- 5.2.4. By Distribution Channel
- 5.2.4.1. Hospital Pharmacies
- 5.2.4.2. Retail Pharmacies
- 5.2.4.3. Online Pharmacies
- 5.2.5. By Country Share
- 5.2.5.1. United States
- 5.2.5.2. Canada
- 5.2.5.3. Mexico
- 5.2.1. By Targeted Bacteria
- 5.3. Country Market Assessment
- 5.3.1. United States Phage Therapy Market Outlook, 2018-2032F*
- 5.3.1.1. Market Size Analysis & Forecast
- 5.3.1.1.1. By Value
- 5.3.1.2. Market Share Analysis & Forecast
- 5.3.1.2.1. By Targeted Bacteria
- 5.3.1.2.1.1. Escherichia coli
- 5.3.1.2.1.2. Staphylococcus aureus
- 5.3.1.2.1.3. Streptococcus
- 5.3.1.2.1.4. Pseudomonas aeruginosa
- 5.3.1.2.1.5. Salmonella
- 5.3.1.2.1.6. Other Bacteria
- 5.3.1.2.2. By Indication
- 5.3.1.2.2.1. Urinary Tract Infections
- 5.3.1.2.2.2. Chronic Otitis
- 5.3.1.2.2.3. Dental Extraction
- 5.3.1.2.2.4. Chronic Ulcerative Colitis
- 5.3.1.2.2.5. Bone Infection
- 5.3.1.2.2.6. Wound and Skin Infections
- 5.3.1.2.2.7. Cystic Fibrosis
- 5.3.1.2.2.8. Others
- 5.3.1.2.3. By Route of Administration
- 5.3.1.2.3.1. Oral
- 5.3.1.2.3.2. Topical
- 5.3.1.2.3.3. Parenteral
- 5.3.1.2.4. By Distribution Channel
- 5.3.1.2.4.1. Hospital Pharmacies
- 5.3.1.2.4.2. Retail Pharmacies
- 5.3.1.2.4.3. Online Pharmacies
- 5.3.1.2.1. By Targeted Bacteria
- 5.3.1.1. Market Size Analysis & Forecast
- 5.3.2. Canada
- 5.3.3. Mexico
- 5.3.1. United States Phage Therapy Market Outlook, 2018-2032F*
All segments will be provided for all regions and countries covered
6. Europe Phage Therapy Market Outlook, 2018-2032F
- 6.1. Germany
- 6.2. France
- 6.3. Italy
- 6.4. United Kingdom
- 6.5. Russia
- 6.6. Netherlands
- 6.7. Spain
- 6.8. Turkey
- 6.9. Poland
7. Asia-Pacific Phage Therapy Market Outlook, 2018-2032F
- 7.1. India
- 7.2. China
- 7.3. Japan
- 7.4. Australia
- 7.5. Vietnam
- 7.6. South Korea
- 7.7. Indonesia
- 7.8. Philippines
8. South America Phage Therapy Market Outlook, 2018-2032F
- 8.1. Brazil
- 8.2. Argentina
9. Middle East and Africa Phage Therapy Market Outlook, 2018-2032F
- 9.1. Saudi Arabia
- 9.2. UAE
- 9.3. South Africa
10. Demand Supply Analysis
11. Value Chain Analysis
12. Porter's Five Forces Analysis
13. PESTLE Analysis
14. Pricing Analysis
15. Market Dynamics
- 15.1. Market Drivers
- 15.2. Market Challenges
16. Market Trends and Developments
17. Regulatory Framework and Innovation
- 17.1. Regulatory Approvals
- 17.2. Clinical Trials
18. Patent Landscape
19. Case Studies
20. Competitive Landscape
- 20.1. Competition Matrix of Top 5 Market Leaders
- 20.2. SWOT Analysis for Top 5 Players
- 20.3. Key Players Landscape for Top 10 Market Players
- 20.3.1. PhagoMed Biopharma GmbH
- 20.3.1.1. Company Details
- 20.3.1.2. Key Management Personnel
- 20.3.1.3. Products and Services
- 20.3.1.4. Financials (As Reported)
- 20.3.1.5. Key Market Focus and Geographical Presence
- 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
- 20.3.2. Armata Pharmaceuticals, Inc.
- 20.3.3. Eligo Bioscience S.A.S.
- 20.3.4. Intralytix, Inc.
- 20.3.5. Locus Biosciences Inc.
- 20.3.6. MicroPhage, Inc.
- 20.3.7. Aziya immunopreparat LLC
- 20.3.8. Sensei Biotherapeutics Inc.
- 20.3.9. Eliava BioPreparations LTD
- 20.3.10. PhagePro, PBC
- 20.3.1. PhagoMed Biopharma GmbH
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.
21. Strategic Recommendations
22. About Us and Disclaimer
List of Tables
- Table 1. Competition Matrix of Top 5 Market Leaders
- Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
- Table 3. About Us - Regions and Countries Where We Have Executed Client Projects
List of Figures
- Figure 1. Global Phage Therapy Market, By Value, In USD Million, 2018-2032F
- Figure 2. Global Phage Therapy Market Share (%), By Targeted Bacteria, 2018-2032F
- Figure 3. Global Phage Therapy Market Share (%), By Indication, 2018-2032F
- Figure 4. Global Phage Therapy Market Share (%), By Route of Administration, 2018-2032F
- Figure 5. Global Phage Therapy Market Share (%), By Distribution Channel, 2018-2032F
- Figure 6. Global Phage Therapy Market Share (%), By Region, 2018-2032F
- Figure 7. North America Phage Therapy Market, By Value, In USD Million, 2018-2032F
- Figure 8. North America Phage Therapy Market Share (%), By Targeted Bacteria, 2018-2032F
- Figure 9. North America Phage Therapy Market Share (%), By Indication, 2018-2032F
- Figure 10. North America Phage Therapy Market Share (%), By Route of Administration, 2018-2032F
- Figure 11. North America Phage Therapy Market Share (%), By Distribution Channel, 2018-2032F
- Figure 12. North America Phage Therapy Market Share (%), By Country, 2018-2032F
- Figure 13. United States Phage Therapy Market, By Value, In USD Million, 2018-2032F
- Figure 14. United States Phage Therapy Market Share (%), By Targeted Bacteria, 2018-2032F
- Figure 15. United States Phage Therapy Market Share (%), By Indication, 2018-2032F
- Figure 16. United States Phage Therapy Market Share (%), By Route of Administration, 2018-2032F
- Figure 17. United States Phage Therapy Market Share (%), By Distribution Channel, 2018-2032F
- Figure 18. Canada Phage Therapy Market, By Value, In USD Million, 2018-2032F
- Figure 19. Canada Phage Therapy Market Share (%), By Targeted Bacteria, 2018-2032F
- Figure 20. Canada Phage Therapy Market Share (%), By Indication, 2018-2032F
- Figure 21. Canada Phage Therapy Market Share (%), By Route of Administration, 2018-2032F
- Figure 22. Canada Phage Therapy Market Share (%), By Distribution Channel, 2018-2032F
- Figure 23. Mexico Phage Therapy Market, By Value, In USD Million, 2018-2032F
- Figure 24. Mexico Phage Therapy Market Share (%), By Targeted Bacteria, 2018-2032F
- Figure 25. Mexico Phage Therapy Market Share (%), By Indication, 2018-2032F
- Figure 26. Mexico Phage Therapy Market Share (%), By Route of Administration, 2018-2032F
- Figure 27. Mexico Phage Therapy Market Share (%), By Distribution Channel, 2018-2032F
- Figure 28. Europe Phage Therapy Market, By Value, In USD Million, 2018-2032F
- Figure 29. Europe Phage Therapy Market Share (%), By Targeted Bacteria, 2018-2032F
- Figure 30. Europe Phage Therapy Market Share (%), By Indication, 2018-2032F
- Figure 31. Europe Phage Therapy Market Share (%), By Route of Administration, 2018-2032F
- Figure 32. Europe Phage Therapy Market Share (%), By Distribution Channel, 2018-2032F
- Figure 33. Europe Phage Therapy Market Share (%), By Country, 2018-2032F
- Figure 34. Germany Phage Therapy Market, By Value, In USD Million, 2018-2032F
- Figure 35. Germany Phage Therapy Market Share (%), By Targeted Bacteria, 2018-2032F
- Figure 36. Germany Phage Therapy Market Share (%), By Indication, 2018-2032F
- Figure 37. Germany Phage Therapy Market Share (%), By Route of Administration, 2018-2032F
- Figure 38. Germany Phage Therapy Market Share (%), By Distribution Channel, 2018-2032F
- Figure 39. France Phage Therapy Market, By Value, In USD Million, 2018-2032F
- Figure 40. France Phage Therapy Market Share (%), By Targeted Bacteria, 2018-2032F
- Figure 41. France Phage Therapy Market Share (%), By Indication, 2018-2032F
- Figure 42. France Phage Therapy Market Share (%), By Route of Administration, 2018-2032F
- Figure 43. France Phage Therapy Market Share (%), By Distribution Channel, 2018-2032F
- Figure 44. Italy Phage Therapy Market, By Value, In USD Million, 2018-2032F
- Figure 45. Italy Phage Therapy Market Share (%), By Targeted Bacteria, 2018-2032F
- Figure 46. Italy Phage Therapy Market Share (%), By Indication, 2018-2032F
- Figure 47. Italy Phage Therapy Market Share (%), By Route of Administration, 2018-2032F
- Figure 48. Italy Phage Therapy Market Share (%), By Distribution Channel, 2018-2032F
- Figure 49. United Kingdom Phage Therapy Market, By Value, In USD Million, 2018-2032F
- Figure 50. United Kingdom Phage Therapy Market Share (%), By Targeted Bacteria, 2018-2032F
- Figure 51. United Kingdom Phage Therapy Market Share (%), By Indication, 2018-2032F
- Figure 52. United Kingdom Phage Therapy Market Share (%), By Route of Administration, 2018-2032F
- Figure 53. United Kingdom Phage Therapy Market Share (%), By Distribution Channel, 2018-2032F
- Figure 54. Russia Phage Therapy Market, By Value, In USD Million, 2018-2032F
- Figure 55. Russia Phage Therapy Market Share (%), By Targeted Bacteria, 2018-2032F
- Figure 56. Russia Phage Therapy Market Share (%), By Indication, 2018-2032F
- Figure 57. Russia Phage Therapy Market Share (%), By Route of Administration, 2018-2032F
- Figure 58. Russia Phage Therapy Market Share (%), By Distribution Channel, 2018-2032F
- Figure 59. Netherlands Phage Therapy Market, By Value, In USD Million, 2018-2032F
- Figure 60. Netherlands Phage Therapy Market Share (%), By Targeted Bacteria, 2018-2032F
- Figure 61. Netherlands Phage Therapy Market Share (%), By Indication, 2018-2032F
- Figure 62. Netherlands Phage Therapy Market Share (%), By Route of Administration, 2018-2032F
- Figure 63. Netherlands Phage Therapy Market Share (%), By Distribution Channel, 2018-2032F
- Figure 64. Spain Phage Therapy Market, By Value, In USD Million, 2018-2032F
- Figure 65. Spain Phage Therapy Market Share (%), By Targeted Bacteria, 2018-2032F
- Figure 66. Spain Phage Therapy Market Share (%), By Indication, 2018-2032F
- Figure 67. Spain Phage Therapy Market Share (%), By Route of Administration, 2018-2032F
- Figure 68. Spain Phage Therapy Market Share (%), By Distribution Channel, 2018-2032F
- Figure 69. Turkey Phage Therapy Market, By Value, In USD Million, 2018-2032F
- Figure 70. Turkey Phage Therapy Market Share (%), By Targeted Bacteria, 2018-2032F
- Figure 71. Turkey Phage Therapy Market Share (%), By Indication, 2018-2032F
- Figure 72. Turkey Phage Therapy Market Share (%), By Route of Administration, 2018-2032F
- Figure 73. Turkey Phage Therapy Market Share (%), By Distribution Channel, 2018-2032F
- Figure 74. Poland Phage Therapy Market, By Value, In USD Million, 2018-2032F
- Figure 75. Poland Phage Therapy Market Share (%), By Targeted Bacteria, 2018-2032F
- Figure 76. Poland Phage Therapy Market Share (%), By Indication, 2018-2032F
- Figure 77. Poland Phage Therapy Market Share (%), By Route of Administration, 2018-2032F
- Figure 78. Poland Phage Therapy Market Share (%), By Distribution Channel, 2018-2032F
- Figure 79. South America Phage Therapy Market, By Value, In USD Million, 2018-2032F
- Figure 80. South America Phage Therapy Market Share (%), By Targeted Bacteria, 2018-2032F
- Figure 81. South America Phage Therapy Market Share (%), By Indication, 2018-2032F
- Figure 82. South America Phage Therapy Market Share (%), By Route of Administration, 2018-2032F
- Figure 83. South America Phage Therapy Market Share (%), By Distribution Channel, 2018-2032F
- Figure 84. South America Phage Therapy Market Share (%), By Country, 2018-2032F
- Figure 85. Brazil Phage Therapy Market, By Value, In USD Million, 2018-2032F
- Figure 86. Brazil Phage Therapy Market Share (%), By Targeted Bacteria, 2018-2032F
- Figure 87. Brazil Phage Therapy Market Share (%), By Indication, 2018-2032F
- Figure 88. Brazil Phage Therapy Market Share (%), By Route of Administration, 2018-2032F
- Figure 89. Brazil Phage Therapy Market Share (%), By Distribution Channel, 2018-2032F
- Figure 90. Argentina Phage Therapy Market, By Value, In USD Million, 2018-2032F
- Figure 91. Argentina Phage Therapy Market Share (%), By Targeted Bacteria, 2018-2032F
- Figure 92. Argentina Phage Therapy Market Share (%), By Indication, 2018-2032F
- Figure 93. Argentina Phage Therapy Market Share (%), By Route of Administration, 2018-2032F
- Figure 94. Argentina Phage Therapy Market Share (%), By Distribution Channel, 2018-2032F
- Figure 95. Asia-Pacific Phage Therapy Market, By Value, In USD Million, 2018-2032F
- Figure 96. Asia-Pacific Phage Therapy Market Share (%), By Targeted Bacteria, 2018-2032F
- Figure 97. Asia-Pacific Phage Therapy Market Share (%), By Indication, 2018-2032F
- Figure 98. Asia-Pacific Phage Therapy Market Share (%), By Route of Administration, 2018-2032F
- Figure 99. Asia-Pacific Phage Therapy Market Share (%), By Distribution Channel, 2018-2032F
- Figure 100. Asia-Pacific Phage Therapy Market Share (%), By Country, 2018-2032F
- Figure 101. India Phage Therapy Market, By Value, In USD Million, 2018-2032F
- Figure 102. India Phage Therapy Market Share (%), By Targeted Bacteria, 2018-2032F
- Figure 103. India Phage Therapy Market Share (%), By Indication, 2018-2032F
- Figure 104. India Phage Therapy Market Share (%), By Route of Administration, 2018-2032F
- Figure 105. India Phage Therapy Market Share (%), By Distribution Channel, 2018-2032F
- Figure 106. China Phage Therapy Market, By Value, In USD Million, 2018-2032F
- Figure 107. China Phage Therapy Market Share (%), By Targeted Bacteria, 2018-2032F
- Figure 108. China Phage Therapy Market Share (%), By Indication, 2018-2032F
- Figure 109. China Phage Therapy Market Share (%), By Route of Administration, 2018-2032F
- Figure 110. China Phage Therapy Market Share (%), By Distribution Channel, 2018-2032F
- Figure 111. Japan Phage Therapy Market, By Value, In USD Million, 2018-2032F
- Figure 112. Japan Phage Therapy Market Share (%), By Targeted Bacteria, 2018-2032F
- Figure 113. Japan Phage Therapy Market Share (%), By Indication, 2018-2032F
- Figure 114. Japan Phage Therapy Market Share (%), By Route of Administration, 2018-2032F
- Figure 115. Japan Phage Therapy Market Share (%), By Distribution Channel, 2018-2032F
- Figure 116. Australia Phage Therapy Market, By Value, In USD Million, 2018-2032F
- Figure 117. Australia Phage Therapy Market Share (%), By Targeted Bacteria, 2018-2032F
- Figure 118. Australia Phage Therapy Market Share (%), By Indication, 2018-2032F
- Figure 119. Australia Phage Therapy Market Share (%), By Route of Administration, 2018-2032F
- Figure 120. Australia Phage Therapy Market Share (%), By Distribution Channel, 2018-2032F
- Figure 121. Vietnam Phage Therapy Market, By Value, In USD Million, 2018-2032F
- Figure 122. Vietnam Phage Therapy Market Share (%), By Targeted Bacteria, 2018-2032F
- Figure 123. Vietnam Phage Therapy Market Share (%), By Indication, 2018-2032F
- Figure 124. Vietnam Phage Therapy Market Share (%), By Route of Administration, 2018-2032F
- Figure 125. Vietnam Phage Therapy Market Share (%), By Distribution Channel, 2018-2032F
- Figure 126. South Korea Phage Therapy Market, By Value, In USD Million, 2018-2032F
- Figure 127. South Korea Phage Therapy Market Share (%), By Targeted Bacteria, 2018-2032F
- Figure 128. South Korea Phage Therapy Market Share (%), By Indication, 2018-2032F
- Figure 129. South Korea Phage Therapy Market Share (%), By Route of Administration, 2018-2032F
- Figure 130. South Korea Phage Therapy Market Share (%), By Distribution Channel, 2018-2032F
- Figure 131. Indonesia Phage Therapy Market, By Value, In USD Million, 2018-2032F
- Figure 132. Indonesia Phage Therapy Market Share (%), By Targeted Bacteria, 2018-2032F
- Figure 133. Indonesia Phage Therapy Market Share (%), By Indication, 2018-2032F
- Figure 134. Indonesia Phage Therapy Market Share (%), By Route of Administration, 2018-2032F
- Figure 135. Indonesia Phage Therapy Market Share (%), By Distribution Channel, 2018-2032F
- Figure 136. Philippines Phage Therapy Market, By Value, In USD Million, 2018-2032F
- Figure 137. Philippines Phage Therapy Market Share (%), By Targeted Bacteria, 2018-2032F
- Figure 138. Philippines Phage Therapy Market Share (%), By Indication, 2018-2032F
- Figure 139. Philippines Phage Therapy Market Share (%), By Route of Administration, 2018-2032F
- Figure 140. Philippines Phage Therapy Market Share (%), By Distribution Channel, 2018-2032F
- Figure 141. Middle East & Africa Phage Therapy Market, By Value, In USD Million, 2018-2032F
- Figure 142. Middle East & Africa Phage Therapy Market Share (%), By Targeted Bacteria, 2018-2032F
- Figure 143. Middle East & Africa Phage Therapy Market Share (%), By Indication, 2018-2032F
- Figure 144. Middle East & Africa Phage Therapy Market Share (%), By Route of Administration, 2018-2032F
- Figure 145. Middle East & Africa Phage Therapy Market Share (%), By Distribution Channel, 2018-2032F
- Figure 146. Middle East & Africa Phage Therapy Market Share (%), By Country, 2018-2032F
- Figure 147. Saudi Arabia Phage Therapy Market, By Value, In USD Million, 2018-2032F
- Figure 148. Saudi Arabia Phage Therapy Market Share (%), By Targeted Bacteria, 2018-2032F
- Figure 149. Saudi Arabia Phage Therapy Market Share (%), By Indication, 2018-2032F
- Figure 150. Saudi Arabia Phage Therapy Market Share (%), By Route of Administration, 2018-2032F
- Figure 151. Saudi Arabia Phage Therapy Market Share (%), By Distribution Channel, 2018-2032F
- Figure 152. UAE Phage Therapy Market, By Value, In USD Million, 2018-2032F
- Figure 153. UAE Phage Therapy Market Share (%), By Targeted Bacteria, 2018-2032F
- Figure 154. UAE Phage Therapy Market Share (%), By Indication, 2018-2032F
- Figure 155. UAE Phage Therapy Market Share (%), By Route of Administration, 2018-2032F
- Figure 156. UAE Phage Therapy Market Share (%), By Distribution Channel, 2018-2032F
- Figure 157. South Africa Phage Therapy Market, By Value, In USD Million, 2018-2032F
- Figure 158. South Africa Phage Therapy Market Share (%), By Targeted Bacteria, 2018-2032F
- Figure 159. South Africa Phage Therapy Market Share (%), By Indication, 2018-2032F
- Figure 160. South Africa Phage Therapy Market Share (%), By Route of Administration, 2018-2032F
- Figure 161. South Africa Phage Therapy Market Share (%), By Distribution Channel, 2018-2032F
- Figure 162. By Targeted Bacteria Map-Market Size (USD Million) & Growth Rate (%), 2024
- Figure 163. By Indication Map-Market Size (USD Million) & Growth Rate (%), 2024
- Figure 164. By Route of Administration Map-Market Size (USD Million) & Growth Rate (%), 2024
- Figure 165. By Distribution Channel Map-Market Size (USD Million) & Growth Rate (%), 2024
- Figure 166. By Region Map-Market Size (USD Million) & Growth Rate (%), 2024
